[go: up one dir, main page]

MX2018012224A - Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas. - Google Patents

Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.

Info

Publication number
MX2018012224A
MX2018012224A MX2018012224A MX2018012224A MX2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A
Authority
MX
Mexico
Prior art keywords
valproic acid
pharmaceutical formulations
delayed release
release pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
MX2018012224A
Other languages
English (en)
Other versions
MX395521B (es
Inventor
Bergh Niklas
Jern Sverker
Faijerson SÄLJÖ Jonas
Ove Gustafsson Nils
Roger Marcus Mårtensson Hans
Original Assignee
Cereno Scient Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scient Ab filed Critical Cereno Scient Ab
Publication of MX2018012224A publication Critical patent/MX2018012224A/es
Publication of MX395521B publication Critical patent/MX395521B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporciona una formulación farmacéutica que tiene uno o más componentes que comprenden ácido valproico (VPA) y/o una sal farmacéuticamente aceptable de este; y uno o más ácidos secundarios, y que comprende opcionalmente uno o más excipientes farmacéuticamente aceptables. También se proporcionan usos de tales formulaciones.
MX2018012224A 2016-04-08 2017-04-10 Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas MX395521B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606197 2016-04-08
PCT/GB2017/051002 WO2017175013A1 (en) 2016-04-08 2017-04-10 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Publications (2)

Publication Number Publication Date
MX2018012224A true MX2018012224A (es) 2019-05-16
MX395521B MX395521B (es) 2025-03-25

Family

ID=58709491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012224A MX395521B (es) 2016-04-08 2017-04-10 Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas

Country Status (15)

Country Link
US (2) US11395808B2 (es)
EP (1) EP3439649B1 (es)
JP (1) JP6985368B2 (es)
KR (1) KR102438395B1 (es)
CN (2) CN114209667A (es)
AU (1) AU2017246697B2 (es)
CA (1) CA3018043A1 (es)
ES (1) ES2969021T3 (es)
HU (1) HUE064701T2 (es)
IL (1) IL262163B2 (es)
MX (1) MX395521B (es)
PL (1) PL3439649T3 (es)
RU (1) RU2760304C2 (es)
WO (1) WO2017175013A1 (es)
ZA (1) ZA201806766B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
CN113995742B (zh) * 2021-10-22 2023-12-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300111B1 (en) 1987-07-22 1991-10-16 Farvalsa AG A moisture stable solid valproic acid formulation and a method of preparing the same
DE60038536T2 (de) * 1999-09-30 2009-06-10 Penwest Pharmaceuticals Co. Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US20040043026A1 (en) 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20050276848A1 (en) 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
JP2009507081A (ja) 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
PL1937650T3 (pl) 2005-09-08 2011-11-30 Mei Pharma Inc Związki heterocykliczne
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
ATE415151T1 (de) * 2006-01-11 2008-12-15 Teva Pharma Formulierung zur verzögerten freisetzung von valproinsäure und deren derivate
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
US20090312311A1 (en) 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
WO2008027993A2 (en) 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CN101947209B (zh) * 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
ES2842970T3 (es) * 2011-03-09 2021-07-15 Cereno Scient Ab Compuestos y métodos para mejorar la fibrinólisis endógena alterada usando inhibidores de la histona desacetilasa
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2017175010A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途

Also Published As

Publication number Publication date
US11395808B2 (en) 2022-07-26
RU2760304C2 (ru) 2021-11-23
BR112018070626A2 (pt) 2019-02-05
EP3439649B1 (en) 2023-11-15
HUE064701T2 (hu) 2024-04-28
IL262163B1 (en) 2023-03-01
NZ746269A (en) 2024-10-25
AU2017246697B2 (en) 2022-06-02
IL262163A (en) 2018-11-29
CA3018043A1 (en) 2017-10-12
PL3439649T3 (pl) 2024-03-18
EP3439649A1 (en) 2019-02-13
US20190111011A1 (en) 2019-04-18
JP6985368B2 (ja) 2021-12-22
US20230120670A1 (en) 2023-04-20
IL262163B2 (en) 2023-07-01
MX395521B (es) 2025-03-25
KR20180127480A (ko) 2018-11-28
KR102438395B1 (ko) 2022-08-30
JP2019510834A (ja) 2019-04-18
EP3439649C0 (en) 2023-11-15
US12023311B2 (en) 2024-07-02
RU2018137399A (ru) 2020-05-12
AU2017246697A1 (en) 2018-10-04
ES2969021T3 (es) 2024-05-16
CN114209667A (zh) 2022-03-22
CN109414423A (zh) 2019-03-01
ZA201806766B (en) 2024-03-27
WO2017175013A1 (en) 2017-10-12
RU2018137399A3 (es) 2020-06-18

Similar Documents

Publication Publication Date Title
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CY1122951T1 (el) Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf
MX2016015636A (es) Formulaciones cannabinoides estables.
MX2018012224A (es) Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas.
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2019009777A (es) Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
PE20241347A1 (es) MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
PH12017500269A1 (en) Composite formulation for oral administration comprising omega-3 fatty acid esters and statins
TW201613557A (en) Stable aqueous recombinant protein formulations
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
MX2018001989A (es) Formulaciones farmaceuticas.
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares